IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+3.55%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$349M
AUM Growth
+$349M
(-20%)
Cap. Flow
-$46.8M
Cap. Flow
% of AUM
-13.39%
Top 10 Holdings %
Top 10 Hldgs %
42.96%
Holding
198
New
27
Increased
9
Reduced
43
Closed
22
Top Buys
Top Sells
| 1 |
Apellis Pharmaceuticals
APLS
|
$11.5M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$7.89M |
| 3 |
CMPS
Compass Pathways
CMPS
|
$6.85M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
$6.66M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$6.2M |
Sector Composition
| 1 | Healthcare | 97.67% |
| 2 | Consumer Staples | 0.57% |
| 3 | Technology | 0.35% |
| 4 | Financials | 0.21% |
| 5 | Real Estate | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
1
Bicycle Therapeutics
BCYC
$511M
| $37.3M | 5.56% | 613,126 +86,626 | +16% | +$5.27M |
|
2
Kezar Life Sciences
KZR
$28.9M
| $17.1M | 2.54% | +1,020,917 | New | +$17.1M |
|
3
Celldex Therapeutics
CLDX
$1.47B
| $16.2M | 2.41% | 419,216 +148,785 | +55% | +$5.75M |
|
4
Zentalis Pharmaceuticals
ZNTL
$122M
| $16.1M | 2.39% | 191,140 +98,796 | +107% | +$8.3M |
|
5
Gossamer Bio
GOSS
$562M
| $13.2M | 1.97% | 1,166,933 -185,000 | -14% | -$2.09M |
|
|
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $12.4M | 1.84% | 569,029 -4,351 | -0.8% | -$94.6K |
|
7
Milestone Pharmaceuticals
MIST
$156M
| $11.5M | 1.71% | 1,750,043 | – | – |
|
8
Immatics
IMTX
$619M
| $9.91M | 1.48% | 737,546 -145,500 | -16% | -$1.96M |
|
9
Adicet Bio
ACET
$59.9M
| $8.35M | 1.24% | 477,418 +85,000 | +22% | +$1.49M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $8.15M | 1.21% | 75,661 +50,000 | +195% | +$5.39M |
|
|
TCON
11
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $7.45M | 1.11% | 2,691,110 | – | – |
|
12
Biogen
BIIB
$19.4B
| $7.09M | 1.06% | 29,533 -2,710 | -8% | -$650K |
|
13
Vaxcyte
PCVX
$4B
| $7.02M | 1.05% | 295,111 | – | – |
|
14
Seres Therapeutics
MCRB
$166M
| $6.63M | 0.99% | 795,903 +189,349 | +31% | +$1.58M |
|
|
PRDS
15
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $6.55M | 0.98% | +400,000 | New | +$6.55M |
|
|
INBX
16
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $6.54M | 0.97% | 149,850 -140,000 | -48% | -$6.11M |
|
|
AYLA
17
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
| $5.7M | 0.85% | 669,271 +130,332 | +24% | +$1.11M |
|
|
18
Xenon Pharmaceuticals
XENE
$2.98B
| $5.6M | 0.83% | 179,138 -198,300 | -53% | -$6.2M |
|
19
X4 Pharmaceuticals
XFOR
$84.2M
| $5.19M | 0.77% | 2,264,491 -275,426 | -11% | -$631K |
|
|
CMRX
20
DELISTED
Chimerix, Inc.
CMRX
| $5.11M | 0.76% | 795,410 -5,898 | -0.7% | -$37.9K |
|
21
Galapagos
GLPG
$2.07B
| $4.86M | 0.72% | 86,865 | – | – |
|
|
GBT
22
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.8M | 0.72% | +164,082 | New | +$4.8M |
|
|
WHWK
23
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $4.74M | 0.71% | 196,408 +185,000 | +1,622% | +$4.47M |
|
24
scPharmaceuticals
SCPH
$295M
| $4.53M | 0.67% | 901,362 | – | – |
|
25
Cabaletta Bio
CABA
$133M
| $3.68M | 0.55% | 970,398 -217,500 | -18% | -$824K |
|